Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 3, 2001, Pages 223-228

  O'Reilly, Seamus ^b   Hartman, Neil R ^b   Bowling, Katherine M ^b   Rowinsky, Eric K ^b   Donehower, Ross C ^b   Collins, J ^a   Strong, J M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

4 O demethyl penclomedine; Antitumor; Clinical trial; Penclomedine; Pharmacokinetics

Indexed keywords

4 O NORPENCLOMEDINE; DRUG METABOLITE; NEOBEE 1053; PENCLOMEDINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PICOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID TUMOR; AREA UNDER THE CURVE; BIOAVAILABILITY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PICOLINES;

EID: 0034742028     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100346     Document Type: Article

References (17)

1. Preclinical antitumor activity of an alpha picoline derivative, penclomedine (NSC 338720), on human and murine tumors
2. Preclinical antitumor activity of penclomedine in mice: Cross resistance, schedule dependence, and oral activity against tumor xenografts in brain
3. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)pyridine, NSC 338720]
4. Murine and human in in vivo penclomedine metabolism
5. 14C-penclomedine in rats
6. The in vitro metabolism of penclomedine in mouse, rat, and human systems
7. 4-Demethylpenclomedine, an anti-tumor active, potentially non-neurotoxic metabolite of penclomedine
8. Treatment of CNS tumor xenografts with penclomedine and 4-O-demethylpenclomedine
9. Phase I, and pharmacologic study of penclomedine, a novel alkylating agent in patients with solid tumors
10. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy
11. Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 338720 CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously
12. Neuroanatomic studies of the cerebellar toxicity of penclomedine
13. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve
14. The estimate of moments: A technical note
15. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study
16. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor